These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32918792)

  • 21. No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.
    Burlacu R; London J; Fleury A; Sené T; Diallo A; Meyssonnier V; Zeller V; Galland J; Huscenot T; Rubenstein E; Trouiller P; Amathieu R; Kutter J; Blondeel D; Lejour G; Mouly S; Lidove O; Wladimir M; Sène D
    Medicine (Baltimore); 2021 May; 100(21):e26023. PubMed ID: 34032722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
    Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H
    Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
    Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region.
    Maritati F; Cerutti E; Zuccatosta L; Fiorentini A; Finale C; Ficosecco M; Cristiano F; Capestro A; Balestra E; Taruscia D; Vivarelli M; Donati A; Perna GP; Giacometti A; Tavio M; Onesta M; Di Sante L; Ranghino A
    Transpl Infect Dis; 2020 Oct; 22(5):e13377. PubMed ID: 32573895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposed Tocilizumab in Patients with Severe COVID-19.
    Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
    J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 May; 397(10285):1637-1645. PubMed ID: 33933206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute respiratory distress syndrome due to COVID-19. Clinical and prognostic features from a medical Critical Care Unit in Valencia, Spain.
    Ramírez P; Gordón M; Martín-Cerezuela M; Villarreal E; Sancho E; Padrós M; Frasquet J; Leyva G; Molina I; Barrios M; Gimeno S; Castellanos Á
    Med Intensiva (Engl Ed); 2021; 45(1):27-34. PubMed ID: 32919796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of artificial liver blood purification treatment on the survival of critical ill COVID-19 patients.
    Dai X; Zhang Y; Yu L; Jiang YA; Chen L; Chen Y; Li M; Gao C; Shang J; Xiang S; Li Y; Li J; Zhou C; Zhou X; Chen N; Liu Y; Liu J; Zhang Y; Chen X; Zhu D; Gao H; Tang L; Zhu M; Li L
    Artif Organs; 2021 Jul; 45(7):762-769. PubMed ID: 33326621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.
    Moreno-García E; Rico E; Albiach L; Agüero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; García-Pouton N; Garcia-Vidal C; González-Cordón A; Hernández-Meneses M; Inciarte A; Laguno M; Leal L; Linares L; Macay I; Meira F; Mensa J; Moreno A; Morata L; Puerta-Alcalde P; Rojas J; Solá M; Torres B; Torres M; Tomé A; Tuset M; Castro P; Fernández S; Nicolás JM; Almuedo-Riera A; Muñoz J; Fernandez-Pittol M; Marcos MA; Soy D; Martínez JA; García F; Soriano A
    Rev Esp Quimioter; 2021 Jun; 34(3):238-244. PubMed ID: 33829722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
    Singh AK; Oks M; Husk G; Dechario SP; Mina B; Singh K; Kirschenbaum L; Carpati CM; Mahmoud O; Gabra NI; Ishikawa O; Altschultz E; Shah V; Mahajan A; Gautam A; Birnbaum B; Antonacci AC; Raoof S
    Respir Care; 2021 Dec; 66(12):1805-1814. PubMed ID: 34548407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
    Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
    Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
    [No Abstract]   [Full Text] [Related]  

  • 34. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.
    Fisher MJ; Marcos Raymundo LA; Monteforte M; Taub EM; Go R
    Int J Infect Dis; 2021 Feb; 103():536-539. PubMed ID: 33333252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study.
    Chalkias A; Huang Y; Ismail A; Pantazopoulos I; Papagiannakis N; Bitterman B; Anderson E; Catalan T; Erne GK; Tilley CR; Alaka A; Amadi KM; Presswalla F; Blakely P; Bernal-Morell E; Cebreiros López I; Eugen-Olsen J; García de Guadiana Romualdo L; Giamarellos-Bourboulis EJ; Loosen SH; Reiser J; Tacke F; Skoulakis A; Laou E; Banerjee M; Pop-Busui R; Hayek SS;
    Crit Care Med; 2024 Jun; 52(6):930-941. PubMed ID: 38391282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
    Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
    Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune reactivity during COVID-19: Implications for treatment.
    Napoli C; Benincasa G; Criscuolo C; Faenza M; Liberato C; Rusciano M
    Immunol Lett; 2021 Mar; 231():28-34. PubMed ID: 33421440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials.
    Klopfenstein T; Gendrin V; Kadiane-Oussou NJ; Conrozier T; Zayet S;
    Rev Med Virol; 2022 Jan; 32(1):e2239. PubMed ID: 33882179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.